Is ecstasy (MDMA) use associated with symptoms of anxiety or depression among incarcerated juvenile offenders?

Journal of Evidence-Based Social Work

Volumn 2, Issue 3-4, 2005, Pages 19-34

  Vaughn, Michael G ^a   Howard, Matthew O ^b   Curtis, Mary P ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c MARYVILLE UNIVERSITY   (United States)

Author keywords

Adolescent drug use; Incarcerated youth; Juvenile justice; Juvenile offenders; Substance abuse

Indexed keywords

EID: 34248611960     PISSN: 15433714     EISSN: 15433722     Source Type: Journal    
DOI: 10.1300/J394v02n03_02     Document Type: Article

References (31)

1. Bilchik, S., 1998. Mental health disorders and substance abuse problems among juveniles, Washington, DC:U.S. Department of Justice, Office of Justice Programs, Office of Juvenile Justice, and Delinquency Prevention. Fact Sheet #82
2. Bolla, K. I., McCann, U. D., and Ricaurte, G. A., 1998. Memory impairment in abstinent MDMA (“Ecstasy”) users. Neurology, 51:1532–1537.
3. Derogatis, L. R., 1993. Brief symptom inventory:Administration, scoring, and procedures manual, Minneapolis, MN:National Computer Systems, Inc.
4. Derogatis, L. R., and Savitz, K. L., 2000. “The SCL-90-R and brief symptom inventory (BSI) in primary care”. In Handbook of psychological assessment in primary care settings, Edited by:Maruish, M. E., 297–334. Mahwah, NJ:Lawrence Erlbaum Associates.
5. Fox, J., 1991. Regression Diagnostics, Newbury Park, CA:Sage.
6. Gerra, G., Amimovic, A., Ferri, M., Zambelli, U., Timpano, M., Neri, E., Franco, G., Marzocchi, G. F., Delsignore, R., and Brambilla, F., 2000. Long-lasting effects of (±) 3, 4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans. Biological Psychiatry, 47:127–136.
7. Hammersley, R., Ditton, J., Smith, I., and Short, E., 1999. Patterns of ecstasy use by drug users. British Journal of Criminology, 39:625–647.
8. Hanson, K. L., and Luciana, M., 2004. Nerocognitive function in users of MDMA:The importance of clinically significant patterns of use. Psychological Medicine, 34:22–246.
9. Harvard Mental Health Letter. July 2001. Harvard Mental Health Letter, July, 5–6. MDMA.
10. Hegadoren, K. M., Baker, G. B., and Bourin, M., 1999. 3, 4-methylenedioxy analogues of amphetamines:Defining the risks to humans. Neuroscience and Biobehavioral Reviews, 23:539–553.
11. Jackson, B., and Reed, A., 1970. Another abusable amphetamine. Journal of the American Medical Association, 211:830
12. Johnston, L. D., O'Malley, P. M., and Bachman, J. G., 2000. Monitoring the future. National results on adolescent drug use:Overview of key findings, 2000, DHHS. National Institute on Drug Abuse
13. Kellett, S., Beail, N., Newman, D. W., and Frankish, P., 2003. Journal of Applied Research in Intellectual Disabilities, 16:127–134.
14. Landry, M. J., 2002. MDMA:A review of epidemiologic data. Journal of Psychoactive Drugs, 34(2):163–169.
15. Lieb, R., Schuetz, C. G., Pfister, H., Von Sydow, K., and Ulrich Wittchen, H., 2002. Mental disorders in ecstasy users:A prospective-longitudinal investigation. Drug and Alcohol Dependence, 68:195–207.
16. McCann, U. D., and Ricaurte, G. A., 1991. Lasting Neuropsychiatric sequaelae of (±) methylenedioxymethamphetamine (‘Ecstasy’) in recreational users. Journal of Clinical Psychopharmacology, 11:302–305.
17. Molliver, M. E., Berger, U. V., Mamounas, L. A., Molliver, D. C., O'Hearn, E., and Wilson, M. A., 1990. Neurotoxicity of MDMA and related compounds:Anatomic studies. Annals of the New York Academy of Sciences, 6000:640–664.
18. Morgan, J. J., 2000. Ecstasy (MDMA):A review of its possible persistent psychological effects. Psychopharmacology, 152:230–248.
19. Nichols, D. E., 1986. Differences between the mechanisms of action of MDMA, MDBD and the classical hallucinogens. Identification of a new therapeutic class:Entactogens. Journal of Psychoactive Drugs, 18:305–313.
20. Nichols, D. E., and Oberiender, R., 1990. “Structure-activity relationships of MDMA and related compounds:A new class of psychoactive agents?”. In Ecstasy:The clinical, pharmacological, and neurotoxicological effects of the drug MDMA, Edited by:Peroutka, S. J., 53–620. Boston, MA:Kluwer, Academic.
21. Office of National Drug Control Policy. 2001. Special topic:“Ecstasy” and other club drugs. Pulse check:Trends in drug abuse mid-year, 2000:56–62.
22. Osterheld, J. R., Armstrong, S. C., and Cozza, K. L., 2004. Ecstasy:Pharmacodynamic and pharmacokinetic interactions. Psychosomatics:Journal of Consultation Liaison Psychiatry, 45:84–87.
23. Pallanti, S., and Mazzi, D., 1992. MDMA (Ecstasy) precipitation of panic disorder. Biological Psychiatry, 32:91–95.
24. Parrott, A. C., Sisk, E., and Turner, J. J.D., 2000. Psychobiological problems in heavy ‘Ecstasy’ (MDMA) polydrug users. Drug and Alcohol Dependence, 60:105–110.
25. Peroutka, S. J., 1987. Incidence of recreational use of 3, 4-methlyenedioxymethamphetamine MDMA, (“Ecstasy”) on an undergraduate campus. New England Journal of Medicine, 317:1542–1543.
26. Ricaurte, G. A., Yuan, J., and McCann, U. D., 2000. ±3, 4-Methylenedioxy methamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity:Studies in animals. Neuropsychobiology, 42:5–10.
27. Rosenbaum, M., 2002. Ecstasy:America's new “reefer madness.”. Journal of Psychoactive Drugs, 34(2):137–142.
28. Schensul, J. J., The diffusion of MDMA use among urban youth in Hartford, CT:Implication for drug and HIV prevention in club drug users and their networks. Presented at MDMA/Ecstasy Research:Advances, Challenges and Future Directions. 2001, Bethesda, MD. http://www.drugabuse.gov/meetings/MDMA/MDMAVideo/MDMA10.ram
29. Substance Abuse and Mental Health Services Administration. July 2001. Year-End 2000 Emergency Department Data from the Drug Abuse Warning Network July, Washington, DC
30. Teplin, L. A., Abram, K. M., McClelland, G. M., Dulcan, M. K., and Mericle, A. A., 2002. Psychiatric disorders in youth in juvenile detention. Archives of General Psychiatry, 59:1133–1143.
31. Yacoubian, G. S., Arria, A. M., Fost, E., and Wish, E. D., 2002. Estimating the prevalence of Ecstasy use among juvenile offenders. Journal of Psychoactive Drugs, 34(2):209–213.